Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.
For the treatment of premature ejaculation.
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2005/09/21 | Phase 3 | Completed | Alza Corporation, DE, USA |
Sign in to access additional FDA-approved products with detailed regulatory information.
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
---|
No FDA products found for this drug
Sign in to access additional EMA-approved products with authorization details.
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
---|
No EMA products found for this drug
Sign in to access additional HSA-approved products with regulatory information.
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. |
---|
No HSA products found for this drug
Sign in to access additional NMPA-approved products with approval information.
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
---|---|---|---|---|---|---|---|---|---|
国药准字H20249570 | 片剂 | N/A | 30mg(按C₂₁H₂₃NO计) | Chemical Drug | Approved | 2024/12/01 | Domestic | ||
国药准字H20249684 | 片剂 | N/A | 30mg(按C₂₁H₂₃NO计) | Chemical Drug | Approved | 2024/12/06 | Domestic | ||
国药准字H20243544 | 片剂 | N/A | 30mg(按C₂₁H₂₃NO计) | Chemical Drug | Approved | 2024/04/17 | Domestic | ||
国药准字H20243216 | 片剂 | N/A | 30mg(按C₂₁H₂₃NO计) | Chemical Drug | Approved | 2024/02/23 | Domestic | ||
国药准字H20244118 | 片剂 | N/A | 60mg(按C₂₁H₂₃NO计) | Chemical Drug | Approved | 2024/06/25 | Domestic | ||
国药准字H20223926 | 片剂 | N/A | 30mg(按C₂₁H₂₃NO计) | Chemical Drug | Approved | 2022/12/30 | Domestic | ||
国药准字H20203553 | 片剂 | N/A | 60mg(按C21H23NO计) | Chemical Drug | Approved | 2020/11/04 | Domestic | ||
国药准字H20234541 | 片剂 | N/A | 30mg(按C₂₁H₂₃NO计) | Chemical Drug | Approved | 2023/11/21 | Domestic | ||
国药准字H20234684 | 片剂 | N/A | 60mg(按C₂₁H₂₃NO计) | Chemical Drug | Approved | 2023/12/26 | Domestic | ||
国药准字H20234304 | 片剂 | N/A | 30mg(按C₂₁H₂₃NO计) | Chemical Drug | Approved | 2023/10/18 | Domestic |
Product Name | Registration Code | Company | Category | Sale Type | Reg. Date |
---|
No PPB products found for this drug
Sign in to access additional TGA-approved products with licensing information.
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
---|
No TGA products found for this drug